Ophthalmic surgical devices, contact lens solutions, and diagnostic equipment contacting eyes demand rigorous safety assessment - the eye's exquisite sensitivity means even mild irritants cause severe discomfort, vision impairment, or permanent damage. Ocular irritation testing using the validated Draize rabbit eye test provides critical safety assessment for devices with potential eye contact through controlled application with systematic scoring. The protocol involves precise application techniques specific to test material form - liquids, solids, or aerosols - with standardized scoring capturing immediate and delayed responses including conjunctival redness, chemosis, corneal opacity, and iris inflammation. Essential device categories include ophthalmic surgical devices contacting ocular tissues during procedures, contact lens care products applied directly to lenses worn on cornea, diagnostic equipment like tonometers touching eyes during examination, and devices used near eyes during medical or cosmetic procedures. Standardized Draize scoring enables classification from non-irritant through severe irritant categories with regulatory acceptance worldwide, while results support device labeling and patient warnings about eye contact risks. The 72-hour observation period captures delayed responses that immediate assessment misses, revealing cumulative damage or inflammatory cascades developing after initial exposure. For ophthalmic devices, the testing validates materials won't cause corneal damage, lens opacification, or inflammatory responses compromising vision. Contact lens solutions require rigorous testing ensuring cleaning and disinfection agents don't irritate eyes even with daily use. The rabbit model provides conservative assessment as rabbit eyes generally prove more sensitive than human eyes, providing safety margins protecting patients from unexpected ocular toxicity.

Animal testing faces increasing ethical scrutiny and regulatory restrictions - validated alternative methods reducing animal use while maintaining predictive accuracy represent the future of safety assessment. In vitro skin irritation testing per ISO 10993-23 using MatTek EpiDerm™ reconstructed human epidermis provides human-relevant safety assessment while eliminating animal use through validated tissue construct methodology. The validated protocol exposes tissue constructs to test materials with subsequent MTT viability assessment providing quantitative data that predicts human skin responses, correlating with in vivo Draize scores through established prediction models. The reconstructed human epidermis model incorporates normal human keratinocytes forming stratified epithelium with functional barrier properties including stratum corneum, providing physiologically relevant tissue responses. Regulatory acceptance continues expanding with EU authorities preferring in vitro methods when validated alternatives exist, while global harmonization efforts promote alternative method adoption reducing animal testing. For medical device manufacturers, in vitro irritation testing provides earlier safety assessment during development screening materials before expensive in vivo studies, enables efficient material comparison testing multiple candidates rapidly, and demonstrates corporate responsibility regarding animal welfare. The quantitative viability data enables dose-response assessment revealing concentration-dependent effects, supporting formulation optimization minimizing irritation while maintaining functionality. Manufacturing validation confirms processing doesn't increase skin irritation potential, sterilization doesn't generate irritating degradation products, and aging maintains acceptable irritation profiles throughout shelf life. The human-derived tissue provides more relevant prediction of human responses than animal models, potentially reducing clinical surprises from species differences in skin sensitivity or metabolism.